Clinical trials: HIV Infection
HIV
Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
The purpose of the study is to measure the drug levels in the blood of HIV-infected individuals taking anti- HIV medication efavirenz 400 mg once daily in the presence of anti-TB medication rifampicin and isoniazid.
- Trial name
- NCT02832778
- Testing
- Efavirenz, tenofovir /emtricitabine, tenofovir/lamivudine
- Where
- 2 sites in Uganda, United Kingdom
- Volunteers
- 35 people
- Sponsor
- St Stephens Aids Trust
Pneumonia, Pneumocystis Carinii, HIV Infections
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)
To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3.
- Trial name
- NCT00002043
- Testing
- Dapsone
- Where
- United States
- Sponsor
- Jacobus Pharmaceutical
HIV, Cardiovascular Disease
Healing Hearts and Mending Minds in Older Adults Living With HIV
The purpose of this study is to see if exercise is helpful for improving memory, concentration thinking abilities, physical function, and quality of life for adults aged 50 to 89 years living with HIV and who have two or more…
- Conditions
- HIV, Cardiovascular Disease, AIDS
- Trial name
- FitBrain (NCT02711878)
- Testing
- Let's Move Program, Let's Flex Program, Group Motivational Interviewing
- Where
- 3 sites in United States
- Volunteers
- 115 people
- Sponsor
- Emory University
HIV Infections
Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum
The purpose of this study was to evaluate the pharmacokinetics, feasibility, acceptability, and safety of a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as oral daily pre-exposure…
- Trial name
- NCT03386578
- Testing
- Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Behavioral HIV risk reduction package, Enhanced adherence support
- Where
- 7 sites in Malawi, South Africa and 2 more
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-infection/Aids, Malnutrition
Impact of RUTF on Body Composition, Anemia and Zinc Status of PLWHA
A clinical trial was conducted in 65 PLWH randomly allocated to receive standard hospital diet alone (Control group: n=33), or the diet combined with 100 g/day of RUTF (RUTF group: n=32).
- Trial name
- PLWHA (NCT02433743)
- Testing
- Ready-to-use therapeutic food (RUTF)
- Where
- Senegal
- Volunteers
- 65 people
- Sponsor
- Cheikh Anta Diop University, Senegal
Hiv, Fatigue
Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS
This is an integrated medication/behavioral intervention program to increase energy, activity level and goal attainment in a sample of HIV+ adults whose presenting problems include both clinically significant fatigue and unmet…
- Conditions
- Hiv, Fatigue, Goals
- Trial name
- NCT01158443
- Testing
- Behavioral Activation Therapy, Supportive Counseling
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
HIV Prevention
Pre-exposure Prophylaxis (PrEP) Adherence for Black MSM
The goal of this clinical trial is to learn if two interventions-C4 and C4+3MV-can improve PrEP adherence (taking medication to prevent HIV) among Black men who have sex with men (MSM).
- Trial name
- C4+3MV (NCT06661343)
- Testing
- C4 Program, C4 + 3MV Program
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV Infections, Tuberculosis
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
To evaluate the methodology for rapidly determining the early bactericidal activity (EBA), tolerance, and pharmacokinetics of isoniazid and levofloxacin in the treatment of pulmonary tuberculosis (TB).
- Trial name
- NCT00000778
- Testing
- Isoniazid, Pyridoxine hydrochloride, Levofloxacin
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)
Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and…
- Conditions
- Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV, HBV, HCV
- Trial name
- MAGICS IBCS (NCT07170748)
- Where
- 2 sites in Côte d’Ivoire, Kenya
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- MagIA Diagnostics
HIV Infections
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
This study examines the long-term effects of interleukin-2 (IL-2) in combination with anti-HIV drugs, or highly active antiretroviral therapy (HAART).
- Trial name
- NCT00000923
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 12 sites in United States
- Volunteers
- 110 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Two Tests for Anti-HIV Drug Resistance
The purpose of this study is to compare 2 different types of tests of the HIV virus to see which specific anti-HIV drugs would work the best. Drug resistance is a major reason for therapy failure in HIV patients.
- Trial name
- NCT00006490
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acceptability of Health Care, HIV Primary Infection
A Multicomponent Intervention to Address Gender-based Violence in HIV
This project seeks to adapt and pilot a trauma-informed combination intervention named 'Kickin' it with the Gurlz' that was designed with, for, and by transgender women of color to improve HIV prevention continuum outcomes.
- Trial name
- NCT04799197
- Testing
- Kicking it with the Gurlz
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Michigan
HIV
Research In Viral Eradication of HIV Reservoirs
This study will be a two-arm prospective 1:1 randomised controlled trial comparing: Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART preferably including raltegravir (cART) plus…
- Trial name
- RIVER (NCT02336074)
- Testing
- Combination Antiretroviral Therapy (cART), Raltegravir, Vorinostat
- Where
- 6 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
HIV Infections
Study to Evaluate the Replacement of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors by Nevirapine in Patients on Triple Treatment With Analogues Only
The purpose of this study is to evaluate the proportion of patients with viral load of HIV-1 < 50 copies after 48 weeks of follow-up after randomization to change or not to nevirapine.
- Trial name
- NCT00415090
- Testing
- Nevirapine
- Where
- 17 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Hospital de Calella
HIV Infections
A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex
To determine the safety, pharmacokinetics (blood levels), and effectiveness of didanosine (ddI) when administered both intravenously and orally.
- Trial name
- NCT00000710
- Testing
- Didanosine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus Transmission
PC4PrEP: Integrating PrEP Into Primary Care
Oral pre-exposure prophylaxis (PrEP) has been proven effective in reducing HIV infection in high-risk men who have sex with men, heterosexually active women and men, and injecting drug users.
- Trial name
- PC4PrEP (NCT03617874)
- Testing
- PC4PrEP- Intervention Clinics, Standard of Care Clinics
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
HIV Infections
Viral Load Triggered ART Care in Lesotho
This cluster randomized clinical trial at 18 nurse-led rural health centers in Lesotho will test an automated differentiated service delivery model using viral load results, other clinical characteristics and participants'…
- Trial name
- VITAL (NCT04527874)
- Testing
- VITAL model
- Where
- 18 sites in Lesotho
- Volunteers
- 5,809 people
- Sponsor
- Swiss Tropical & Public Health Institute
HIV
Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study
Immunosuppressed patients are at increased risk for complications of influenza infection, including secondary pneumonia and are recommended for annual influenza vaccination.
- Trial name
- NCT02031874
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Miami
HIV Infections
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)
The aim of this study was to determine if virologically suppressed human immunodeficiency virus type 1 (HIV-1) infected adults on an antiretroviral regimen (including 2 nucleoside reverse transcriptase inhibitors [NRTIs] plus a…
- Trial name
- NCT02429791
- Testing
- DTG 50 mg, RPV 25 mg, CAR
- Where
- 65 sites in United States, Argentina and 11 more
- Volunteers
- 510 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
To evaluate the safety and immunogenicity of live recombinant canarypox ALVAC-HIV vCP205 in combination with recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) at 80 microg and 250 microg.
- Trial name
- NCT00001090
- Testing
- APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim
- Where
- 4 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)